CQ Pharmaceutical subsidiary issues first 2025 medium-term notes

Chongqing Pharmaceutical (Group) Co., Ltd., a controlled subsidiary of CQ Pharmaceutical Holding Co., Ltd., has successfully completed the issuance of its first tranche of 2025 medium-term notes. The company had previously registered 2 bn yuan in medium-term notes with the National Association of Financial Market Institutional Investors on December 2, 2024, allowing for phased issuance over 24 months.

The first tranche of notes, identified as "25 渝医药 MTN001" with code 102584456, was issued on October 24, 2025, with funds totaling 200m yuan credited on October 27, 2025. The notes carry an interest rate of 2.29% and were issued at a price of 100 yuan per 100 yuan face value, with a maturity of "2+N" years and a redemption date of December 31, 2099.

To date, under the registration approval, Chongqing Pharmaceutical has cumulatively issued two tranches of medium-term notes (including this issue), totaling 1.2 bn yuan, leaving a remaining quota of 800m yuan. Guotai Haitong Securities Co., Ltd. acted as the lead underwriter, with Bank of China Co., Ltd. as the co-underwriter.